Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCIBC Private Wealth Group, LLC
Latest Disclosed Ownership200,425 shares
Latest Disclosed Value $ 79,699,001
CIBC Private Wealth Group, LLC reports 6.44% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On February 12, 2026 - CIBC Private Wealth Group, LLC filed a 13F-HR form disclosing ownership of 200,425 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $67,723,608 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 24, 2025 disclosing 214,213 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -6.44% during the quarter. The current value of the position is $52,210,712 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,425 -13,788 -6.44 79,699 -18.41 0.1347
2025-11-24 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 214,213 -4,116 -1.89 97,681 37.20 0.1672
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 218,329 12,818 6.24 71,195 54.43 0.1272
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 205,511 2,143 1.05 46,100 -5.76 0.0974
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 203,368 -5,118 -2.45 48,920 -14.68 0.0887
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 208,486 2,095 1.02 57,340 8.90 0.1028
2024-08-09 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 206,391 32,142 18.45 52,652 97.07 0.0988
2024-05-10 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 174,249 548 0.32 26,718 -19.64 0.0523
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 173,701 -429 -0.25 33,248 7.82 0.0704
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 174,130 -382 -0.22 30,838 -6.96 0.0730
2023-11-21 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 174,512 53,531 44.25 33,147 36.77 0.0725
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 174,512 53,531 33,147 0.0725
2023-11-21 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 120,981 -885 -0.73 24,235 -15.22 0.0537
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 120,981 -885 24,235 0.0527
2023-06-01 2022-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 121,866 2,458 2.06 28,585 19.60 0.0960
2023-02-14 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 121,866 2,458 28,961 0.0606
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 121,866 2,458 28,961 0.0000
2022-11-15 2022-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 119,408 3,166 2.72 23,901 40.98 0.0644
2022-08-03 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 116,242 -4,035 -3.35 16,953 -13.68 0.0440
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,277 2,025 1.71 19,640 -2.05 0.0429
2022-04-04 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 118,252 -893 -0.75 20,052 -10.86 0.0416
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 118,252 -893 20,052 0.0416
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 119,145 429 0.36 22,494 11.77 0.0523
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 118,716 -7,544 -5.97 20,126 12.90 0.0462
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 126,260 126,260 17,827 0.0449
2018-08-02 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5 -100.00 0 -100.00
2018-05-17 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5 -7,550 -99.93 1 -99.90 0.0000
2018-02-12 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,555 7,555 960 0.0041
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.